Back
Supernus Pharmaceuticals Quote, Financials, Valuation and Earnings
Sell
31
SUPN
Supernus Pharmaceuticals
Last Price:
29.25
Seasonality Move:
14.18%
7 Day Trial
ALL ACCESS PASS
$
7
Supernus Pharmaceuticals Price Quote
$29.25
+0.51 (+1.77%)
(Updated: May 16, 2024 at 6:55 PM ET)
Supernus Pharmaceuticals Key Stats
Sell
31
Supernus Pharmaceuticals (SUPN)
is a Sell
Day range:
$28.65 - $29.57
52-week range:
$21.99 - $35.96
Dividend yield:
0%
P/E ratio:
1,437.00
P/S ratio:
2.65
P/B ratio:
1.7%
Volume:
381.6K
Avg. volume:
417.3K
1-year change:
-17.27%
Market cap:
$1.6B
Revenue:
$607.5M
EPS:
$-0.29
How Much Does Supernus Pharmaceuticals Make?
-
How Much Are Supernus Pharmaceuticals's Sales Annually?
SUPN Revenues are $607.5M -
How Much Profit Does Supernus Pharmaceuticals's Make A Year?
SUPN net income is $1.3M
Is Supernus Pharmaceuticals Growing As A Company?
-
What Is Supernus Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.07% -
What Is Supernus Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is -0.99%
Supernus Pharmaceuticals Stock Price Performance
-
Did Supernus Pharmaceuticals Stock Go Up Last Month?
Supernus Pharmaceuticals share price went down by -4.17% last month -
Did SUPN's Share Price Rise Over The Last Year?
SUPN share price fell by -17.27% over the past 1 year
What Is Supernus Pharmaceuticals 52-Week High & Low?
-
What Is Supernus Pharmaceuticals’s 52-Week High Share Price?
Supernus Pharmaceuticals has traded as high as $35.96 over the past 52 weeks -
What Is Supernus Pharmaceuticals’s 52-Week Low Share Price?
Supernus Pharmaceuticals has traded as low as $21.99 over the past 52 weeks
Supernus Pharmaceuticals Price To Free Cash Flow
-
Is Supernus Pharmaceuticals Stock Overvalued?
Supernus Pharmaceuticals is trading at a price to free cash flow ratio of 15.84 -
Is Supernus Pharmaceuticals Stock Undervalued?
Supernus Pharmaceuticals EV to Free Cash Flow ratio is 12.84 -
What Is Supernus Pharmaceuticals’s Price Earnings Growth Ratio?
SUPN PEG ratio is 0.00 -
Is Supernus Pharmaceuticals Trading At A Premium To Earnings?
Supernus Pharmaceuticals EV to EBIT ratio is 0.00
Is It Risky To Buy Supernus Pharmaceuticals?
-
How Much Debt Does Supernus Pharmaceuticals Have?
Total long term debt quarterly is $0 -
How Much Cash Does Supernus Pharmaceuticals Have?
Cash and short term investments quarterly total is $297.7M -
What Is Supernus Pharmaceuticals’s Book Value Per Share?
Book value per share is 16.90
Is Supernus Pharmaceuticals Cash Flow Positive?
-
What Is SUPN Cash Flow From Operations?
Cash flow from operations (TTM) is $100.4M -
What Is Supernus Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$476.5M -
What Is Supernus Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$22.7M
Supernus Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
SUPN return on invested capital is -1.53% -
What Is Supernus Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is -1.12% -
What Is SUPN Return On Equity?
ROE is a measure of profitability and is -1.69%
Supernus Pharmaceuticals Earnings Date & Stock Price
-
What Is Supernus Pharmaceuticals's Stock Price Today?
A single share of SUPN can be purchased today for 28.74 -
What Is Supernus Pharmaceuticals’s Stock Symbol?
Supernus Pharmaceuticals trades on the nasdaq under the ticker symbol: SUPN -
When Is Supernus Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Supernus Pharmaceuticals is scheduled on August 8, 2024 -
When Is SUPN's next ex-dividend date?
Supernus Pharmaceuticals's next ex-dividend date is May 7, 2020 -
How To Buy Supernus Pharmaceuticals Stock?
You can buy Supernus Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Supernus Pharmaceuticals Competitors
-
Who Are Supernus Pharmaceuticals's Competitors?
Below is a list of companies who compete with Supernus Pharmaceuticals or are related in some way:
Supernus Pharmaceuticals Dividend Yield
Data Unavailable
Supernus Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | -99.23% | 0% |
| Revenue: | -6.58% | -1.5% |
Analyst Recommendations
| Buy Recommendations: | 1 |
|---|---|
| Hold Recommendations: | 1 |
| Sell Recommendations: | 0 |
| Price Target: | 40.67 |
| Upside from Last Price: | 41.5% |